On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis

PLoS ONE

Volumn 2, Issue 6, 2007, Pages

  Greenstein, Robert J ^a   Su, Liya ^a   Shahidi, Azra ^a   Brown, Sheldon T ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFAPYRIDINE;

ANIMAL; ARTICLE; CATTLE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; MYCOBACTERIUM PARATUBERCULOSIS; PARATUBERCULOSIS; PATHOGENICITY; PATHOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATTLE; DRUG THERAPY, COMBINATION; HUMANS; MESALAMINE; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PARATUBERCULOSIS; SULFAPYRIDINE;

EID: 35648962939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000516     Document Type: Article

References (24)

1. Svartz N, (1942) Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta Medica Scandinavica 110: 577-598.
2. Berardi RR, (1996) Inflammatory Bowel Disease. In: Herfindal ET, Gourley DR, editors. Textbook of Therapeutics Drugs and Disease Management Baltimore Williams and Wilkins pp. 483-502.
3. Travis SP, (2002) Which 5-ASA? Gut 51: 548-549.
4. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, et al.(1998) Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 12: 1207-1216.
5. Stenson WF, Korznik J, (2003) Inflammatory Bowel Disease. In: Yamada T, editors. Textbook of Gastroenterology. Fourth ed Philadelphia PA.19106 USA Lippincott Williams & Wilkins pp. 1727-1828.
6. Whitby LEH, (1938) Chemotherapy of pneumoccal and other infections with 2-(p aminobenzenesulphonamido) pyridine. Lancet 1: 1210-1212.
7. Evans GM, Gaisford WF, (1938) Treatment of pneumonia with 2-(p aminobenzenesulphonamido) pyridine. Lancet 2: 14-19.
8. Azad Khan AK, Piris J, Truelove SC, (1977) An experiment to determine the active therapeuric moiety of sulphasalazine. Lancet 2: 829-831.
9. Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ, (1996) On the etiology of Crohn disease. Proc Natl Acad Sci U S A 93: 9816-9820.
10. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST, (2007) On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis. PLoS ONE 2: e161.
11. Greenstein RJ, Collins MT, (2004) Emerging pathogens: is Mycobacterium avium subspecies paratuberculosis zoonotic? Lancet 364: 396-397.
12. Naser SA, Ghobrial G, Romero C, Valentine JF, (2004) Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 364: 1039-1044.
13. Hermon-Taylor J, El-Zaatari FAK, (2004) The Mycobacterium avium subspecies paratuberculosis problem and its relation to the causation of Crohn disease. In: Pedley S, Bartram J, Rees G, Dufour A, Cotruvo J, editors. Pathogenic Mycobacteria in Water: A Guide to Public Health Consequences, Monitoring and Management. 1 ed London UK IWA Publishing pp. 74-94.
14. Greenstein RJ, (2003) Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis 3: 507-514.
15. Choi PM, Targan SR, (1994) Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 39: 1885-1892.
16. Rutgeerts P, (1998) Medical therapy of inflammatory bowel disease. Digestion 59: 453-469.
17. Chiodini RJ, Van Kruiningin HJ, Thayer WJ Jr, Coutu J, (1986) Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. JClinMicrobiol 24: 357-363.
18. Bertram MA, Inderlied CB, Yadegar S, Kolanoski P, Yamada JK, et al.(1986) Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis 154: 194-195.
19. Damato JJ, Collins MT, (1990) Growth of Mycobacterium paratuberculosis in radiometric, Middlebrook and egg-based media. Vet Microbiol 22: 31-42.
20. Rastogi N, Goh KS, Labrousse V, (1992) Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. AntimicrobAgents Chemother 36: 2843-2846.
21. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, et al.(1995) Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332: 292-297.
22. Zanetti S, Molicotti P, Cannas S, Ortu S, Ahmed N, et al.(2006) "In vitro" activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's disease and paratuberculosis. Ann Clin Microbiol Antimicrob 5: 27.
23. Britton WJ, Lockwood DN, (2004) Leprosy. Lancet 363: 1209-1219.
24. (1964) Ethical Principles for Medical Research Involving Human Subjects (The Helsinki Declaration of Human Rights). World Medical Association. http://www.wma.net/e/policy/b3.htm. Accessed May 20, 2007.